American Superconductor Corporation vs Eli Lilly And Co — how do they compare? American Superconductor Corporation trades at $32.58 (market cap $1.56B), while Eli Lilly And Co trades at $1,219.37 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 692.3× American Superconductor Corporation's market cap, and Eli Lilly And Co pays a 0.57% dividend while American Superconductor Corporation pays none. Which is the better fit depends on your goals.
| AMSC | LLY | |
|---|---|---|
Market Cap | $1.56B | $1.08T |
Sector | Technology | Health |
52-Week High | $66.68 | $1.24K |
52-Week Low | $25.95 | $639.43 |
Enterprise Value | $1.42B | $1.13T |
Dividend Yield | — | 0.57% |
Signals from Pluang's Aura AI — not financial advice
AMSC trades at $33.19, up 7.1% today, showing strong momentum despite a bearish technical signal. The company reported record Q1 2026 revenue of $94.1 million, up 30% year-over-year, but missed earnings estimates due to margin pressure. Analyst consensus leans bullish with 53% buy ratings, while technical indicators show resistance at $34 and support at $30.
Outlook remains mixed with strong revenue growth and record backlog providing visibility, but margin compression and aggressive valuation pose risks. The stock offers growth potential in energy infrastructure markets, though investors should monitor execution on profitability targets amid increasing competition.
Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.
LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.
Trailing returns across standard periods
Latest headlines on both assets
AMSC provides energy technology solutions for smarter and cleaner power grids. It offers wind turbine electronic controls and advanced grid systems that enhance the reliability and efficiency of renewable energy networks.
Read more on AMSC →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →